This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe
Save the date!
November 6–8, 2023Munich, Germany

Youth Bio Global

Profile

YOUTH BIO GLOBAL has established for the patient who suffers from the rare and incurable disease providing the universal coverage in 2017 and has a high potential stem cell technology which can be the most promising therapeutics for various types of ischemic vascular diseases. Xeno free EPC technology had certified with NET (New Excellent Technology) by Ministry of Health and Welfare and aslo designated as an innovative product by Korean government. We are proud that have world 1st and the only xeno free EPC (endothelial progenitor cell) technology derived from human umbilical cord blood which represents both angiogenesis and vasculogenesis for ischemic vascular diseases such as criticl limb ischemia, myocardiac infarction, diabetic retinopathy and stroke, etc. Now, we focus on developing first-in-class EPC therapeutics for the patients with critical limb ischemia and diabetic foot ulcer, designated as a fast track by US FDA.